Title:
MRNA THERAPEUTIC VACCINE FOR TREATMENT OF ATHEROTHROMBOSIS
Document Type and Number:
WIPO Patent Application WO/2023/244957
Kind Code:
A3
Abstract:
Described herein are mRNA-based and peptide-based therapeutic vaccines comprising modified TNFR2 sequences complementary to variants of Homo sapiens TNFR2 genes and methods for treating subjects having atherosclerosis. Atherosclerosis is a systemic dysfunctional endothelial, focal occurring, chronic inflammatory, fiber-proliferative, prothrombotic, angiogenic, multifactorial disease of the arterial caused by the retention of modified low-density lipoproteins, hemodynamic, and reductive oxidative (redox) stress. There is no question that atherosclerosis is a systemic dysfunctional endothelial disease. Inflammation in the setting of the vulnerable plaque is the body's natural protective response to ischemic injury of the vessel wall providing oxygen and metabolic nourishment as the intima undergoes a positive outward remodeling and thickening, while at the same time may contribute to plaque growth through the response to injury mechanism to intraplaque hemorrhage (IPH).
Inventors:
IVERSEN PATRICK (US)
KIPSHIDZE NODAR (US)
KIPSHIDZE NICKOLAS (US)
KIPSHIDZE NODAR (US)
KIPSHIDZE NICKOLAS (US)
Application Number:
PCT/US2023/068270
Publication Date:
February 08, 2024
Filing Date:
June 12, 2023
Export Citation:
Assignee:
ATHEROVAX LLC (US)
International Classes:
A61K39/00; A61K31/711
Foreign References:
| US20200109121A1 | 2020-04-09 | |||
| US20070249538A1 | 2007-10-25 | |||
| US20160016900A1 | 2016-01-21 | |||
| US20200149026A1 | 2020-05-14 |
Attorney, Agent or Firm:
BROWN, Bernard, A. (US)
Download PDF: